Ampio Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Ampio Pharmaceuticals ont diminué à un taux annuel moyen de -28.9%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 12.9% par an.

Informations clés

-28.9%

Taux de croissance des bénéfices

-22.8%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie	7.3%
Taux de croissance des recettes	n/a
Rendement des fonds propres	-163.7%
Marge nette	n/a
Dernière mise à jour des bénéfices	30 Sep 2023

Mises à jour récentes des performances passées

Pas de mise à jour

Recent updates

Ventilation des recettes et des dépenses

Comment Ampio Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

DB:APH Recettes, dépenses et bénéfices (USD Millions )
Date	Les revenus	Dépenses G+A	Dépenses de R&D
30 Sep 23	-9	8	2
30 Jun 23	-14	10	4
31 Mar 23	-15	12	6
31 Dec 22	-16	11	9
30 Sep 22	-20	14	13
30 Jun 22	-18	12	13
31 Mar 22	-19	10	13
31 Dec 21	-17	9	12
30 Sep 21	-15	6	9
30 Jun 21	-15	6	8
31 Mar 21	-14	6	7
31 Dec 20	-16	7	9
30 Sep 20	-12	7	13
30 Jun 20	-16	7	14
31 Mar 20	-13	7	15
31 Dec 19	-14	6	13
30 Sep 19	-11	5	9
30 Jun 19	2	4	6
31 Mar 19	6	4	6
31 Dec 18	34	4	7
30 Sep 18	-11	5	9
30 Jun 18	-21	5	10
31 Mar 18	-28	5	11
31 Dec 17	-52	5	10
30 Sep 17	-12	5	9
30 Jun 17	-12	6	8
31 Mar 17	-14	6	8
31 Dec 16	-19	7	11
30 Sep 16	-22	8	13
30 Jun 16	-23	8	15
31 Mar 16	-24	9	16
31 Dec 15	-22	9	15
30 Sep 15	-26	9	18
30 Jun 15	-30	11	21
31 Mar 15	-33	11	23
31 Dec 14	-30	9	22
30 Sep 14	-36	12	25
30 Jun 14	-32	10	23
31 Mar 14	-30	9	22
31 Dec 13	-24	7	17
30 Sep 13	-20	6	14
30 Jun 13	-17	6	12
31 Mar 13	-13	4	9
31 Dec 12	-12	6	6

Des revenus de qualité: APH n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: APH n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: APH n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 28.9% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de APH au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: APH n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 28.7% ).

Rendement des fonds propres

ROE élevé: APH a un retour sur capitaux propres négatif ( -163.68% ), car il n'est actuellement pas rentable.

Ampio Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69

Ventilation des recettes et des dépenses

Historique des gains et des recettes

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Rendement des fonds propres

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé